Dov Elefant Insider Profile
4 Followers
Dov Elefant, CFO at Femasys, holds 15.63K shares in Femasys (Ticker: FEMY), holds 11.76K shares in Cellectar Biosciences (Ticker: CLRB), holds 0.00 shares in Akari Therapeutics (Ticker: AKTX). Most recently, Dov Elefant Bought ― shares of Femasys on Aug 11, 2026 for an estimated value of $50.00K.
Profitable Transactions
2 out of 4 Profitable Transactions
Average Return
-16.60%
Average return per transaction
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Dov Elefant holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Buy
Date:Jun 08, 2020 - Jun 08, 2021
Return:+28.80%
The most profitable trade made by Dov Elefant
Dov Elefant's Trading History
Femasys
Aug 11, 2026
CFO
Informative Buy
50.00K
$43.59K
Cellectar Biosciences
Dec 28, 2020
CFO
Informative Buy
10.00K
$29.86K
Akari Therapeutics
―
CFO
―
$0.00
Immune Pharmaceuticals
―
―
―
$0.00
List of latest transactions for each holding click on a transaction to see Dov Elefant's performance on stock
You May Also Like
Dov Elefant insider profile FAQ
What is the percentage of profitable transactions made by Dov Elefant?
The percentage of profitable transactions made by Dov Elefant is 50%.
What is the average return per transaction made by Dov Elefant?
The average return per transaction made by Dov Elefant is -16.60%.
What stocks does Dov Elefant hold?
Dov Elefant holds: FEMY, CLRB, AKTX, IMNPQ stocks.
What was Dov Elefant’s latest transaction?
Dov Elefant latest transaction was an Informative Buy of $50.00K.
What was Dov Elefant's most profitable transaction?
Dov Elefant’s most profitable transaction was an Informative Buy of CLRB stock on June 8, 2020. The return on the trade was 28.80%.
What is Dov Elefant's role in Femasys?
Dov Elefant's role in Femasys is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.